Effects of cytokines on CD20 antigen expression on tumor cells from patients with chronic lymphocytic leukemia

Leukemia Research

Volumn 24, Issue 5, 2000, Pages 411-415

  Venugopal, Parameswaran ^a   Sivaraman, Smitha ^a   Huang, Xiao Ke ^a   Nayini, Jaya ^a   Gregory, Stephanie A ^a   Preisler, Harvey D ^a  

^a RUSH CANCER INSTITUTE   (United States)

Author keywords

B cell lymphoma; CD 20; Chronic lymphocytic leukemia; Cytokines

Indexed keywords

CD20 ANTIGEN; CYTOKINE; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 4; MONOCLONAL ANTIBODY; STEM CELL FACTOR; THROMBOPOIETIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN EXPRESSION; ARTICLE; CELL KILLING; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FLOW CYTOMETRY; HUMAN; HUMAN CELL; NONHODGKIN LYMPHOMA; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; TUMOR CELL;

ANTIGENS, CD20; CYTOKINES; FLOW CYTOMETRY; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; UP-REGULATION;

EID: 0033995976     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(99)00206-4     Document Type: Article

References (25)

1. Valentine M.A., Meier K.E., Rossie S., Clark E.A. Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes. J. Biol. Chem. 264(19):1989;11282-11287.
2. Einfeld D.A., Brown J.P., Valentine M.A., Clark E.A., Ledbetter J.A. Molecular cloning of the human CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J. 7(3):1998;711-717.
3. Anderson K.C., Bates M.P., Slaughenboupt B.L., Pinkus G.S., Schlossman S.F., Nadler L.M. Expression of human B Cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood. 63(6):1984;1424-1433.
4. Stashenko P., Nadler L.M., Hardy R., Schlossman S.F. Characterization of a human B lymphocyte-specific antigen. J. Immunol. 125:1980;1678-1685.
5. Schriever F., Freedman A.S., Freedman G., Messner E., Lee G., Daley J. et al. Isolated human follicular dendritic cells display a unique antigenic phenotype. J. Exp. Med. 169:1989;2043-2058.
6. Anderson K.C., Bates M.P., Slaughernhoupt B.L., Pinkus G.S., Schlossman S.F., Nadler L.M. Expression of human B cell-associated antigens on leukemias and lymphomas. A model of human B cell differentiation. Blood. 63:1984;1424-1433.
7. Maloney D.G., Grillo-Lopez A.J., White C.A., Bodkin D., Schilder R.J., Neidhart J.A. et al. IDEC C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood. 90(6)(2):1997;2188-2195.
8. Reff M.E., Carner K., Chambers K.S., Chinn P.C., Leonard J.E., Raab R. et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 83:1994;435-445.
9. Maloney D.G., Leler T.M., Czerwinski D.K., Waldichuk C., Rosenberg J., Grillo-Lopez A. et al. Phase I clinical trial using escalating single dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood. 84:1994;2457-2466.
10. McLaughlin P., Grillo-Lopez A.J., Link B.K., Levy R., Czuczman M., Williams M.E. et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. 16:1998;2825-2833.
11. Maloney D.G., Grillo-Lopez A.J., Bodkin D., White C., Foon K., Schilder R.J. et al. IDEC-C2B8 anti-CD20 antibody: results of long term follow-up of relapsed NHL phase II patients. Blood. 86:1995;54a.
12. Ohnishi K., Bonavida B. Regulation of B-cell lymphoma growth in syngeneic SJL/mice. Establishment of tumor dormancy following administration of anti-CD4 monoclonal antibody into tumor-bearing mice. Leukemia. 7:1993;1801-1806.
13. Morimoto H., Yonehara S., Bonavida B. Overcoming tumor necrosis and drug resistance of human tumor cell lines by combination treatment with anti-fas antibody and drugs or toxins. Cancer Res. 53:1993;2591-2596.
14. Safrit J.T., Berek J.S., Bonavida B. Sensitivity of drug resistant human ovarian tumor cell lines to combined effects of tumor necrosis factor (TNF-α) and doxorubicin, failure of the combination to modulate the MDR phenotype. Gynecol. Oncol. 48:1992;214-220.
15. Venugopal P, Sivaraman S, Huang, Chopra H, Raza A, Preisler H. Upregulation of CD20 antigen expression in CLL cells by in vitro exposure to cytokines, Blood 1998;92(10)(Suppl 1)(part 1 of 2):247a (abstr #1009).
16. Trehu E.G., Isner J.M., Mier J.W., Karp D.D., Atkins M.B. Possible myocardial toxicity associated with interleukin-4 therapy. J. Immunother. 14(4):1993;348-351.
17. Margolin K., Aronson F.R., Sznol M., Atkins M.B., Gucalp R., Fisher R.I. et al. Phase II studies of recombinant human interleukin-4 in advanced renal cancer and malignant cancer. J. Immunother. 15(2):1994;147-153.
18. Stadler W.M., Rybak M.E., Vogelzang N.J. A phase II study of subcutaneous recombinant human interleukin-4 in metastatic renal cell carcinoma. Cancer. 76(9):1995;1629-1633.
19. Dillman R.O. Antibody therapy. Oldham R.K. Principles of Cancer Biotherapy. 3rd edn:1998;Klluwer Academic Publishers.
20. Knox S.J., Goris M.L., Trisler K., Negrin R., Davis T., Liles T. et al. Yittrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin. Cancer Res. 2:1996;457-470.
21. Kaminski M.S., Zasadny K.R., Francis I.R., Fenner M.C., Ross C.W., Milik A.W. et al. Iodine-131 anti-B1 radioimmunotherapy for B-cell lymphoma. J. Clin. Oncol. 14:1996;1974-1981.
22. Czuczman MS, Grillo-Lopez AJ, White CA, Saleh M, Gordon L, LoBuglio AF, Jonas C, Dallaire B, Varns C. IDEC-C2B8 chemoimmunotherapy in patients with low-grade lymphoma, Blood 1996;86:453a, abstr #1799.
23. Demidem A., Lam T., Alas S., Hariharan K., Hanna N., Bonavida B. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Chemother. Radiopharm. 12(3):1997;177-186.
24. Davis T, Maloney D, White CA, Grillo-Lopez AJ, Williams M, Weiner G, Sklenar T, Levy R. Combination immunotherapy of low grade or follicular (LG/F) non-hodgkin's lymphoma with rituximab and α interferon: interim analysis. Proc. Am. Soc. Clin. Oncol. 1998;17:11a, abstract #39.
25. Maloney D.G., Smith B., Applebaum F.R. The anti-tumor effect of monoclonal antiCD20 antibody (mAb) therapy includes direct antiproliferative activity and induction of apoptosis in CD20 positive non-Hodgkin's lymphoma (NHL) cell lines. Blood. 8:1996;A2535.